These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 6595259)

  • 1. Predicting the susceptibility of anaerobes to cefoperazone, cefotaxime, and cefoxitin with the thioglycolate broth disk procedure.
    Zabransky RJ; Birk RJ; Kurzynski TA; Toohey KL
    J Clin Microbiol; 1986 Aug; 24(2):181-5. PubMed ID: 3745418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of broth disk elution methods for susceptibility testing of anaerobic bacteria with the newer beta-lactam antibiotics.
    Jorgensen JH; Redding JS; Howell AW
    J Clin Microbiol; 1986 Mar; 23(3):545-50. PubMed ID: 3514661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of in vitro methods for testing ceftriaxone against anaerobic bacteria, including quality control guidelines.
    Barry AL; Jones RN
    J Clin Microbiol; 1988 Apr; 26(4):776-7. PubMed ID: 2896669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of Bacteroides and Fusobacterium spp. from foot rot in goats to 10 beta-lactam antibiotics.
    Piriz Duran S; Valle Manzano J; Cuenca Valera R; Vadillo Machota S
    Antimicrob Agents Chemother; 1990 Apr; 34(4):657-9. PubMed ID: 2344172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordant results between the broth disk elution and broth microdilution susceptibility tests with Bacteroides fragilis group isolates.
    Aldridge KE; Henderberg A; Schiro DD; Sanders CV
    J Clin Microbiol; 1990 Feb; 28(2):375-8. PubMed ID: 2312684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaerobic susceptibility tests with single breakpoint concentrations.
    Barry AL
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):849-50. PubMed ID: 2086222
    [No Abstract]   [Full Text] [Related]  

  • 7. Review of methods for susceptibility testing of anaerobes.
    Zabransky RJ
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1025-31. PubMed ID: 1295756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefotetan: a review of the microbiologic properties and antimicrobial spectrum.
    Jones RN
    Am J Surg; 1988 May; 155(5A):16-23. PubMed ID: 3287964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of susceptibility of anaerobic bacteria to cefotetan and cefoxitin by the thioglycolate disk elution method.
    Barry AL; Packer RR
    J Clin Microbiol; 1984 Nov; 20(5):912-6. PubMed ID: 6595259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods.
    Jones RN; Barry AL; Fuchs PC; Thornsberry C
    J Clin Microbiol; 1986 Dec; 24(6):1055-9. PubMed ID: 3097064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter study of the in vitro antianaerobic activity of cefotetan compared with other antimicrobial agents.
    Zabransky RJ; Bobey DG; Sheikh W
    Am J Surg; 1988 May; 155(5A):47-51. PubMed ID: 3163901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria.
    Aldridge KE
    Clin Ther; 1990; 12 Suppl C():3-12. PubMed ID: 2202509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.
    Ayers LW; Jones RN; Barry AL; Thornsberry C; Fuchs PC; Gavan TL; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1982 Nov; 22(5):859-77. PubMed ID: 6983862
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.